UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
______________________
 
FORM 8-K
 
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
August 8, 2013
Date of Report (Date of earliest event reported)
 
BOVIE MEDICAL CORPORATION
(Exact name of registrant as specified in its Charter)
 
 
 
Delaware
 
012183
 
11-2644611
(State or other jurisdiction
 of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
 
734 Walt Whitman Road, Melville, New York 11747
(Address of principal executive offices) (Zip Code)
 
(631) 421-5452
Registrant's telephone number, including area code
 
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
 

 

Item 8.01. Other Events
 
In connection with the previously disclosed litigation pending in the United States District Court for the Middle District of Florida between Bovie Medical Corporation (the “Company”) and Leonard Keen, our former Vice President and General Counsel, on August 8, 2013, following a jury trial, the jury returned a verdict in favor of Mr. Keen awarding him $622,500 in severance.  In addition, the jury determined that, Mr. Keen’s previously issued 110,000 stock options should be reinstated and accelerated, and that the terms of the indemnification provision pertaining to Mr. Keen’s service as an employee of the Company contained in Mr. Keen’s prior employment agreement is enforceable.  Lastly, Mr. Keen was awarded attorney’s fees in an amount to be determined by the Court.  The Company is presently reviewing our options as they pertain to the verdict.
 
 
 
 
 

 
2

 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Date: August 13, 2013
 
BOVIE MEDICAL CORPORATION
     
   
By:   /s/  Andrew Makrides                                                      
   
               Andrew Makrides
   
   Chief Executive Officer and
   Chairman of the Board
 
 

 
3